We are live on
!
Find out more
VAM
Visium Asset Management Portfolio holdings
AUM
$1.43B
1-Year Est. Return
3.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.08B
AUM Growth
+$312M
(+4.6%)
Cap. Flow
+$423M
Cap. Flow
% of AUM
5.97%
Top 10 Holdings %
Top 10 Hldgs %
31.95%
Holding
1,367
New
348
Increased
332
Reduced
294
Closed
358
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$188M |
| 2 |
Labcorp
LH
|
+$183M |
| 3 |
AGN
Allergan Inc
AGN
|
+$144M |
| 4 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$93.8M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$82.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookdale Senior Living
BKD
|
+$104M |
| 2 |
Cardinal Health
CAH
|
+$104M |
| 3 |
AGN
Allergan plc
AGN
|
+$80.7M |
| 4 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$60.3M |
| 5 |
Elevance Health
ELV
|
+$55.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.3% |
| 2 | Consumer Discretionary | 5.38% |
| 3 | Financials | 4.49% |
| 4 | Industrials | 3.37% |
| 5 | Technology | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MJN
926
DELISTED
Mead Johnson Nutrition Company
MJN
| $232K | ﹤0.01% |
+2,300
| New | +$229K |
|
927
Paychex
PAYX
$41.6B
| $230K | ﹤0.01% |
+4,962
| New | +$229K |
|
928
Intel
INTC
$455B
| $226K | ﹤0.01% |
6,210
+310
| +5% | +$10.8K |
|
|
PACW
929
DELISTED
PacWest Bancorp
PACW
| $226K | ﹤0.01% |
+4,960
| New | +$218K |
|
|
PMC
930
DELISTED
PharMerica Corporation
PMC
| $226K | ﹤0.01% |
+10,902
| New | +$259K |
|
931
BorgWarner
BWA
$13.1B
| $225K | ﹤0.01% |
4,646
-716
| -13% | -$34.9K |
|
932
World Acceptance Corp
WRLD
$834M
| $225K | ﹤0.01% |
+2,830
| New | +$209K |
|
|
TWTR
933
DELISTED
Twitter, Inc.
TWTR
| $223K | ﹤0.01% |
6,200
-13,800
| -69% | -$587K |
|
|
MEG
934
DELISTED
Media General, Inc
MEG
| $223K | ﹤0.01% |
+13,297
| New | +$199K |
|
|
PARA
935
DELISTED
Paramount Global Class B
PARA
| $222K | ﹤0.01% |
4,000
-67,502
| -94% | -$3.6M |
|
|
ESRX
936
DELISTED
Express Scripts Holding Company
ESRX
| $219K | ﹤0.01% |
+2,576
| New | +$201K |
|
|
DYN
937
DELISTED
Dynegy, Inc.
DYN
| $219K | ﹤0.01% |
+7,200
| New | +$222K |
|
938
Everest Group
EG
$14.5B
| $218K | ﹤0.01% |
1,279
+32
| +3% | +$5.4K |
|
939
Charter Communications
CHTR
$17.3B
| $217K | ﹤0.01% |
1,300
-5,923
| -82% | -$936K |
|
940
CNX Resources
CNX
$5.06B
| $217K | ﹤0.01% |
+7,676
| New | +$233K |
|
941
Idexx Laboratories
IDXX
$44.1B
| $217K | ﹤0.01% |
+2,920
| New | +$205K |
|
942
Dillards
DDS
$9.19B
| $215K | ﹤0.01% |
1,716
-1,860
| -52% | -$207K |
|
943
Brinker International
EAT
$9.17B
| $215K | ﹤0.01% |
+3,647
| New | +$199K |
|
944
Kimco Realty
KIM
$17.2B
| $214K | ﹤0.01% |
8,481
-1,477
| -15% | -$36.1K |
|
945
D.R. Horton
DHI
$40B
| $213K | ﹤0.01% |
8,400
-598,618
| -99% | -$14M |
|
946
Johnson Controls International
JCI
$88.8B
| $213K | ﹤0.01% |
4,202
-15,089
| -78% | -$737K |
|
947
Invesco BuyBack Achievers ETF
PKW
$1.72B
| $212K | ﹤0.01% |
+4,400
| New | +$203K |
|
948
Alto Ingredients
ALTO
$369M
| $210K | ﹤0.01% |
+20,270
| New | +$247K |
|
949
Omnicom Group
OMC
$21.6B
| $210K | ﹤0.01% |
+2,700
| New | +$197K |
|
950
American Tower
AMT
$80.8B
| $208K | ﹤0.01% |
+2,100
| New | +$206K |
|
Similar funds
FBNAT
CPS
LH
CPM
VFS
ZA
FVFIGP
WA
Visium Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, Visium Asset Management held 1,367 positions worth $7.08B, up 4.6% from $6.77B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Visium Asset Management deployed $423M of net new capital in Q4 2014, opening 348 new positions and adding to 332 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 988,391 shares worth $89.4M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 39% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Brookdale Senior Living, an estimated $104M trimmed.
- Visium Asset Management's largest Q4 2014 buy was BioMarin Pharmaceuticals: 988,391 shares worth $89.4M.
- Visium Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q4 2014, an estimated $188M increase.
- Visium Asset Management's biggest Q4 2014 reduction was Brookdale Senior Living, cutting an estimated $104M.
- Visium Asset Management fully exited AMAG Pharmaceuticals in Q4 2014, selling an estimated $60.3M.
- Visium Asset Management's ten largest holdings make up 32% of its $7.08B portfolio in Q4 2014.
- Visium Asset Management opened 348 new positions and closed 358 in Q4 2014.
- Visium Asset Management's portfolio value rose 4.6% quarter-over-quarter to $7.08B.
Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.